Observation of the clinical efficacy of Guigui Zhuanggu Tablets in the treatment of postmenopausal osteoporotic low back pain based on the theory of

Xiangshan Hospital of Traditional Chinese Medicine, Huangpu District, Shanghai0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) Meet the diagnostic criteria for primary osteoporosis;
•(2) Comply with the syndrome of deficiency of kidney yang and deficiency of liver and kidney in the diagnostic criteria of traditional Chinese medicine;
•(3) Female, 45-75 years old, and natural menopause for more than 1 year;
•(4) Low back pain, VAS <=5 points;
•(5) Sign an informed consent form, willing to accept examinations, treatment, and be able to cooperate with follow-up.

•(1) It is known to be allergic to the medicine ingredients in Caerqi D or Guigui Zhuanggu Tablets;
•(2) Patients with secondary osteoporosis such as hyperparathyroidism, osteomalacia, rheumatoid arthritis, gout, multiple myeloma and other secondary osteoporosis patients with various endocrine diseases ( Such as Cushings disease, hyperthyroidism, hyperparathyroidism, hypothyroidism, diabetes, etc.);
•(3) Patients with low back pain caused by other reasons, such as patients with non-osteoporotic low back pain caused by lumbar fractures, spondylolisthesis, ankylosing spondylitis, lumbar spinal stenosis, lumbar disc herniation, lumbar muscle strain and other diseases;
•(4) Other serious diseases affect bone metabolism;
•(5) Patients with combined fractures requiring surgical treatment;
•(6) Those who have been taking other drugs that affect bone metabolism at the same time for a long time and cannot be stopped immediately;
•(7) Women in breast pregnancy;
•(8) Those who have participated or are participating in other clinical research in the past 3 months.

发起方

Xiangshan Hospital of Traditional Chinese Medicine, Huangpu District, Shanghai